medium

When Volume Matters, Immunoassay Systems Deliver

...with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests assures them an abiding and pivotal position in the clinical landscape. This is especia...

Immunoassay Systems - Your Laboratory Workhorse

...with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests assures them an abiding and pivotal position in the clinical landscape. This is especia...

Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

...her impetus and sales growth forthe company in the medium term, Archimedes has an establisheddevelopment organisation with proprietary enabling technologies fornasal drug delivery and a number of products in development. _____________________________________________ Citigate Dewe Rogerson is registered in...

Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics

... in the field of pediatrics. Pediatricsserves as a medium for expression to the general medical professionas well as pediatricians. The Executive Board and Officers of theAmerican Academy of Pediatrics select articles that appear inPediatrics. The American Academy of Pediatrics is an organizationof 60,000 p...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

...neral, effect sizes arecategorized as small (0.2), medium (0.5) and large (0.8). In the second short-term trial, 304, investigators examined 1mg, 2 mg, 3 mg and 4 mg doses and placebo during nine weeks oftreatment. During the first three weeks, patients started at 1 mgwith doses escalating in once- weekly ...

Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device Combination Product - ChronoDose

...tionand control of the dosing profiles. Using low, medium and highconcentrations, for 16 hours, the model drug permeated eachsubject's skin on multiple occasions, resulting in clear anddistinct peaks and troughs of therapeutically effective andwell-targeted blood plasma concentration levels. Anon-compartmen...

PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy

... the 20, or 50 percent, of patients treated at the medium doselevel demonstrated an increase in the expression of dystrophinpost-treatment. Response did not appear to be dependent on type ofnonsense mutation. Additionally, statistically significant reductions in theconcentrations of muscle-derived creatine...

Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting

...ells were about10-fold greater when the incubating medium pH was lowered from 7.0to 5.4. Previously Access had shown a faster release of platinum aspH is lowered in a simple aqueous system. This study confirms thattumor cell uptake of platinum from ProLindac is enhanced as pH islowered; lowered pH is typica...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

... LHB present in the microbiological culture medium for the pneumococcus. In addition, plates with low-binding surfaces demonstrated 4- to 8-fold reductions in ORI MICs without P80. These findings indicate that the addition of P80 to susceptibility tests minimizes ORI bind...